Lexicon Pharmaceuticals (LXRX) Reports In-Line Q4 EPS

February 21, 2013 6:29 AM EST Send to a Friend
Lexicon Pharmaceuticals (NASDAQ: LXRX) reported Q4 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $218 thousand versus the consensus estimate of $370 thousand.

For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment